Pfiz­er/BioN­Tech makes sur­prise choice in fi­nal dash to Oc­to­ber fin­ish line for Covid-19 vac­cine

Pfiz­er and BioN­Tech have ze­roed in on an mR­NA vac­cine can­di­date to take in­to a piv­otal study — and it’s not the one that got an­a­lysts and in­vestors ex­cit­ed from a re­cent re­lease of da­ta.

On the same day Mod­er­na be­gan the US’ first Phase III Covid-19 vac­cine study, the part­ners an­nounced late in the evening that they have start­ed their own ri­val ef­fort with BNT162b2. A two-dose reg­i­men at a 30 µg dose will be test­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER